Clinical Trial Update: A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing SKLB1028 to salvage chemotherapy in relapsed/refractory FLT3-mutated acute myeloid leukemia is ongoing with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• SKLB1028

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Acute Myeloid Leukemia (AML) | Phase 3 | Status: UNKNOWN